Posts tagged as: best biotech back to homepage
 |
Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug(0) The countdown has begun for Cellceutix to begin testing their lead compound, anti-cancer drug Kevetrin, at Dana-Farber and Beth Israel Deaconess. After a mild setback with Formatech going bankrupt, the company has completed the necessary changes to the Investigational New Drug application related to Quality Control testing and stability studies through a new supplier and added the data to the IND. This is great news for biotech traders and Cellceutix faithful as investors are eager to see the new drug in humans because Read More |
|
Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0) Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug. The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
